Honeywell Aerospace IncHONA

Key highlights

• Full year growth revised lower: The company cut its organic sales growth target to a range of 4% to 5%, down from the previous goal of 7% to 9%, as management aligns its outlook with the limited output capacity of its current supply chain. Profit expectations were also lowered to a range of $4.35 billion to $4.45 billion in adjusted earnings before interest and taxes, which is the money earned from core operations.
• Profit margins squeezed by costs: Adjusted earnings before interest and taxes, which measures the profit from running the business, fell 7% to $995 million. This decline happened because $100 million in one-time costs related to the company's recent spin-off and old inventory charges outweighed the gains from higher sales prices.
• Backlog hits new record: The total value of signed orders for future work reached $18.2 billion, a 9% increase over last year. This growth was led by the Defense and Space division and provides a stable pipeline for a company that just became an independent business.
• Defense and Space facing hurdles: Sales in the Defense and Space division grew by only 3% to $1.8 billion, a slower pace than other segments due to parts shortages and the end of a specific government project. This is a critical area for the company's long-term health as it represents about 40% of total quarterly revenue.
• Supply chain investments accelerating: To fix production delays, the company is qualifying 50 new suppliers in the second half of the year and increasing its spending on specialized factory tools by 20%. These actions are meant to resolve the supply constraints that limited sales growth to 5% this quarter despite high customer demand.

Our take: This was a soft quarter defined by the growing pains of becoming an independent company. While the record $18.2 billion backlog shows that customers still want the product, the lowered full year growth outlook to 5% at most proves that supply chain struggles are holding back the business. We still see a healthy long-term path, but the company must prove it can turn those orders into actual shipments before the investment case regains its full strength.